23andMe to offer users’ medical data to Pfizer for research

Following hard on the heels of its $ 60 million deal with Genentech, personal genetics startup 23andMe has announced an agreement to share its user data and research platform with pharmaceutical giant Pfizer. Although 23andMe is still languishing under FDA restrictions (the company is only permitted to offer ancestry reports and raw genetic data to customers — not medical analysis), its well-organized database of some 640,000 genotyped individuals is proving popular with the medical industry.

“The largest dataset of its kind”

In a press statement announcing the deal, 23andMe spelled out the attractions of its genetic resources: “Researchers can now fully benefit from the largest dataset of its kind, running queries in minutes across…

Continue reading…

The Verge – All Posts

Leave a Comment